proxyvotesnow.com

Home › Companies › APOGEE THERAPEUTICS INC. › 2024-2025

APOGEE THERAPEUTICS INC. 2024-2025 Proxy Voting Records

Compiled from SEC Form N-PX filings and APOGEE THERAPEUTICS INC.’s Form 8-K, filed 2025-07-07 (Item 5.07 on EDGAR). Page generated 02 October 2026.

  • 6Reported items
  • 184Asset managers
  • 1,147Fund votes
  • 2025-06-17Meeting date

Proxy season: 2024-2025 2025-2026

Explore APOGEE THERAPEUTICS INC. in the interactive database Compare manager voting policies

Official 2024-2025 meeting results reported by APOGEE THERAPEUTICS INC.

These tallies are APOGEE THERAPEUTICS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2025-07-07 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

APOGEE THERAPEUTICS INC. — official shareholder meeting results, meeting held 2025-06-17
Ballot itemForAgainst AbstainWithheldBroker non-votesOutcome
Elect Director: Elizabeth M. Lilly 17,448,093191,78920,942 --1,079,473 Majority: yes
Elect Director: Mark A. Pompa 16,601,9471,054,9913,886 --1,079,473 Majority: yes
Proposal 2: An advisory vote to approve the Company's executive compensation. 16,234,5041,392,45633,864 --1,079,473 Majority: yes
Proposal 3: A proposal to ratify the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending February 28, 2026. 18,487,452238,25314,592 ---- Majority: yes

This meeting is also recorded here as 2025-06-25; both records come from the same filing, so the date should be checked against it.

Source: APOGEE THERAPEUTICS INC., Form 8-K, filed with the SEC on 2025-07-07 — read the filing on EDGAR.

How asset managers voted at the APOGEE THERAPEUTICS INC. 2024-2025 meeting

Each item below shows how the 184 asset managers that disclosed a APOGEE THERAPEUTICS INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of APOGEE THERAPEUTICS INC.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

1. VOTE ON THE FREQUENCY OF FUTURE ADVISORY VOTES TO APPROVE OUR NAMED EXECUTIVE OFFICERS' COMPENSATION.

SECTION 14A SAY-ON-PAY VOTES

Combines 3 wordings of this item as funds reported it.

100% fund support · no official result

ONE YEAR 77%1 YEAR 21%

The 180 asset managers below cast 100% of the shares they voted on this item FOR (720,904 for, 0 against).

FOR: 720,904 (1.6%)ABSTAIN: 12,502 (0.0%)ONE YEAR: 34,988,335 (76.8%)1 YEAR: 9,613,167 (21.1%)1YR: 193,895 (0.4%)1-YEAR: 17,344 (0.0%)NOT VOTED: 44 (0.0%)
Largest asset managers voting on “VOTE ON THE FREQUENCY OF FUTURE ADVISORY VOTES TO APPROVE OUR NAMED EXECUTIVE OFFICERS' COMPENSATION.” at APOGEE THERAPEUTICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Fidelity00 00One Year
Vanguard00 00One Year
Wellington00 001 Year
RTW INVESTMENTS, LP00 00One Year
Fairmount Funds Management LLC00 00One Year
VR Adviser, LLC00 00One Year
AllianceBernstein00 00One Year
BlackRock00 001 Year
DRIEHAUS CAPITAL MANAGEMENT LLC00 00One Year
T. Rowe Price00 00One Year
Woodline Partners LP00 00One Year
FRANKLIN ADVISERS INC00 00One Year
PERCEPTIVE ADVISORS LLC692,1760 00For
Janus Henderson00 00One Year
Charles Schwab00 001 Year
FRANKLIN STRATEGIC SERIES00 00One Year
Victory Capital00 00One Year
Siren, L.L.C.00 001 Year
Bridge Builder Trust00 001 Year
Paradigm Biocapital Advisors LP00 00One Year
State Street00 00One Year
Capital Group00 001Yr
Affinity Asset Advisors, LLC00 001 Year
DRIEHAUS MUTUAL FUNDS00 00One Year
Commodore Capital LP00 00One Year

Showing the 25 largest of 180 asset managers. See all 180 in the interactive database.

2. Election of Class II Directors for terms expiring in 2028: Lisa Bollinger, M.D.

DIRECTOR ELECTIONS

Combines 3 wordings of this item as funds reported it.

100% fund support · no official result

FOR 91%9%

The 65 asset managers below cast 100% of the shares they voted on this item FOR (13,515,278 for, 0 against).

FOR: 13,515,278 (91.1%)ABSTAIN: 1,322,797 (8.9%)
Largest asset managers voting on “Election of Class II Directors for terms expiring in 2028: Lisa Bollinger, M.D.” at APOGEE THERAPEUTICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard5,177,3500 00For
Fidelity3,975,2250 00For
T. Rowe Price622,3010 00For
BlackRock594,9820 00For
FRANKLIN STRATEGIC SERIES538,0960 00For
AllianceBernstein438,3410 00For
Bridge Builder Trust7,3630 424,1280Abstain
DRIEHAUS MUTUAL FUNDS00 323,0470Abstain
Charles Schwab276,7930 00For
JANUS INVESTMENT FUND275,6390 00For
AB DISCOVERY GROWTH FUND, INC.250,9010 00For
Hartford225,0770 00For
Victory Capital7580 211,1590Abstain
Capital Group193,8950 00For
Equitable172,7480 00For
JPMorgan108,4160 00For
Columbia Threadneedle106,2790 00For
TIAA104,0070 00For
Principal87,4490 00For
Brinker Capital Destinations Trust9990 83,4940Abstain
QUANTITATIVE MASTER SERIES LLC65,1820 00For
BNY Mellon58,1850 00For
Lincoln Financial27,8000 23,3060For
TRUST FOR PROFESSIONAL MANAGERS00 49,9830Abstain
Goldman Sachs00 47,9960Abstain

Showing the 25 largest of 65 asset managers. See all 65 in the interactive database.

3. Election of Class II Directors for terms expiring in 2028: Nimish Shah

DIRECTOR ELECTIONS

Combines 3 wordings of this item as funds reported it.

100% fund support · no official result

FOR 58%ABSTAIN 42%

The 65 asset managers below cast 100% of the shares they voted on this item FOR (8,659,030 for, 0 against).

FOR: 8,659,030 (58.4%)ABSTAIN: 6,179,045 (41.6%)
Largest asset managers voting on “Election of Class II Directors for terms expiring in 2028: Nimish Shah” at APOGEE THERAPEUTICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard5,177,3500 00For
Fidelity00 3,975,2250Abstain
T. Rowe Price622,3010 00For
BlackRock00 594,9820Abstain
FRANKLIN STRATEGIC SERIES538,0960 00For
AllianceBernstein438,3410 00For
Bridge Builder Trust00 431,4910Abstain
DRIEHAUS MUTUAL FUNDS00 323,0470Abstain
Charles Schwab276,7930 00For
JANUS INVESTMENT FUND275,6390 00For
AB DISCOVERY GROWTH FUND, INC.250,9010 00For
Hartford225,0770 00For
Victory Capital7580 211,1590Abstain
Capital Group193,8950 00For
Equitable143,1810 29,5670For
JPMorgan108,4160 00For
Columbia Threadneedle00 106,2790Abstain
TIAA104,0070 00For
Principal87,4490 00For
Brinker Capital Destinations Trust00 84,4930Abstain
QUANTITATIVE MASTER SERIES LLC00 65,1820Abstain
BNY Mellon58,1850 00For
Lincoln Financial00 51,1060Abstain
TRUST FOR PROFESSIONAL MANAGERS00 49,9830Abstain
Goldman Sachs00 47,9960Abstain

Showing the 25 largest of 65 asset managers. See all 65 in the interactive database.

4. Election of Class II Directors for terms expiring in 2028: Tomas Kiselak

DIRECTOR ELECTIONS

Combines 3 wordings of this item as funds reported it.

100% fund support · no official result

FOR 99.8%

The 65 asset managers below cast 100% of the shares they voted on this item FOR (14,822,961 for, 0 against).

FOR: 14,822,961 (99.9%)ABSTAIN: 15,114 (0.1%)
Largest asset managers voting on “Election of Class II Directors for terms expiring in 2028: Tomas Kiselak” at APOGEE THERAPEUTICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard5,177,3500 00For
Fidelity3,975,2250 00For
T. Rowe Price622,3010 00For
BlackRock594,9820 00For
FRANKLIN STRATEGIC SERIES538,0960 00For
AllianceBernstein438,3410 00For
Bridge Builder Trust431,4910 00For
DRIEHAUS MUTUAL FUNDS323,0470 00For
Charles Schwab276,7930 00For
JANUS INVESTMENT FUND275,6390 00For
AB DISCOVERY GROWTH FUND, INC.250,9010 00For
Hartford225,0770 00For
Victory Capital211,9170 00For
Capital Group193,8950 00For
Equitable172,7480 00For
JPMorgan108,4160 00For
Columbia Threadneedle106,2790 00For
TIAA104,0070 00For
Principal87,4490 00For
Brinker Capital Destinations Trust84,4930 00For
QUANTITATIVE MASTER SERIES LLC65,1820 00For
BNY Mellon58,1850 00For
Lincoln Financial51,1060 00For
TRUST FOR PROFESSIONAL MANAGERS49,9830 00For
Goldman Sachs47,9960 00For

Showing the 25 largest of 65 asset managers. See all 65 in the interactive database.

5. RATIFICATION OF THE APPOINTMENT OF ERNST & YOUNG LLP AS THE COMPANY'S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE YEAR ENDING DECEMBER 31, 2025.

AUDIT-RELATEDMajority of the votes cast: yes

99% Majority: yes · of votes cast

FOR 99%
FOR: 18,487,452AGAINST: 238,253

APOGEE THERAPEUTICS INC.’s own tally for this item (“Proposal 3: A proposal to ratify the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending February 28, 2026.”): 18,487,452 for, 238,253 against, per its Form 8-K filed 2025-07-07 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 58,304,801 outstanding shares: 32% for, 0.5% against (32% of the company cast a for/against vote).

The 65 asset managers below cast 100% of the shares they voted on this item FOR (14,825,573 for, 0 against).

FOR 99.9%
FOR: 14,825,573 (99.9%)ABSTAIN: 12,502 (0.1%)
Largest asset managers voting on “RATIFICATION OF THE APPOINTMENT OF ERNST & YOUNG LLP AS THE COMPANY'S INDEPENDENT REGISTERED PUBLIC ACCOUNTING” at APOGEE THERAPEUTICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard5,177,3500 00For
Fidelity3,975,2250 00For
T. Rowe Price622,3010 00For
BlackRock594,9820 00For
FRANKLIN STRATEGIC SERIES538,0960 00For
AllianceBernstein438,3410 00For
Bridge Builder Trust431,4910 00For
DRIEHAUS MUTUAL FUNDS323,0470 00For
Charles Schwab276,7930 00For
JANUS INVESTMENT FUND275,6390 00For
AB DISCOVERY GROWTH FUND, INC.250,9010 00For
Hartford225,0770 00For
Victory Capital211,9170 00For
Capital Group193,8950 00For
Equitable172,7480 00For
JPMorgan108,4160 00For
Columbia Threadneedle106,2790 00For
TIAA104,0070 00For
Principal87,4490 00For
Brinker Capital Destinations Trust84,4930 00For
QUANTITATIVE MASTER SERIES LLC65,1820 00For
BNY Mellon58,1850 00For
Lincoln Financial51,1060 00For
TRUST FOR PROFESSIONAL MANAGERS49,9830 00For
Goldman Sachs47,9960 00For

Showing the 25 largest of 65 asset managers. See all 65 in the interactive database.

6. Advisory Vote on Say on Pay Frequency

SECTION 14A SAY-ON-PAY VOTES

— fund support · no official result

1-YEAR 66%ONE YEAR 31%

No shares were cast for or against this item by the managers below — every disclosed position was an abstention or was not voted.

1-YEAR: 577,000 (66.4%)ONE YEAR: 267,685 (30.8%)1 YEAR: 24,091 (2.8%)
Largest asset managers voting on “Advisory Vote on Say on Pay Frequency” at APOGEE THERAPEUTICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
ADAGE CAPITAL PARTNERS GP, L.L.C.00 001-Year
JPMorgan00 00One Year
Granahan Investment Management, LLC00 001 Year
Desjardins Global Asset Management Inc.00 00One Year

Largest APOGEE THERAPEUTICS INC. shareholders voting in 2024-2025

Ranked by the number of APOGEE THERAPEUTICS INC. shares each manager voted on the most widely held ballot item of the 2024-2025 meeting, shown as a share of the 58,304,801 shares outstanding at the time of that meeting.

Top APOGEE THERAPEUTICS INC. shareholders by shares voted, 2024-2025
#Asset manager % of shares outstanding
1Fidelity 18.72%
2Vanguard 9.02%
3Wellington 8.48%
4RTW INVESTMENTS, LP 4.65%
5Fairmount Funds Management LLC 3.51%
6VR Adviser, LLC 3.00%
7AllianceBernstein 2.77%
8BlackRock 2.62%
9DRIEHAUS CAPITAL MANAGEMENT LLC 2.51%
10T. Rowe Price 2.47%

Reported APOGEE THERAPEUTICS INC. ownership

Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).

APOGEE THERAPEUTICS INC. beneficial owners on record for the 2024-2025 proxy season
Holder % outstanding Disclosure
FMR (Fidelity) 12.85% 13F
Fairmount Funds Management LLC 11.51% 13D
Wellington Management 9.41% 13F
BlackRock 4.99% 13F
RTW Investments, LP 4.65% 13G
Vanguard Group 3.57% 13F
State Street 2.25% 13F
JPMorgan Chase 1.65% 13F
Franklin Templeton 1.50% 13F
Geode Capital 1.43% 13F

Percentages above are of 58,304,801 shares outstanding, as reported by APOGEE THERAPEUTICS INC. on its Form 10-Q dated 2025-03-31 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from APOGEE THERAPEUTICS INC.’s 10-Q dated 2025-03-31. This page is a static snapshot rebuilt weekly on 02 October 2026; a live search always shows the current data.

At APOGEE THERAPEUTICS INC.'s shareholder meeting held 2025-06-17, in the 2024-2025 proxy season, 184 asset managers reported how they voted in their SEC Form N-PX filings, covering 1,147 separate fund positions. Their filings are grouped here into 6 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. APOGEE THERAPEUTICS INC.'s own Form 8-K tally for this meeting is published below, but no row in it could be matched to the most widely held item, so this page states no certified outcome for that item. On that item — VOTE ON THE FREQUENCY OF FUTURE ADVISORY VOTES TO APPROVE OUR NAMED EXECUTIVE OFFICERS'… — the reporting funds cast 100% of the shares they voted in favour (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). That is the aggregate of those managers' own N-PX disclosures, not the company's certified result, and the funds are a subset of all shareholders.

APOGEE THERAPEUTICS INC. proxy season coverage: 2024-2025 (this page) · 2025-2026.